Biotech IV Monitor

COAG — Hemab Therapeutics Holdings Inc.

$2.2B market cap · 4 upcoming readouts tracked

Clinical trial readout dates for Hemab Therapeutics Holdings Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is July 2027.

Next readoutJuly 2027in ~8 months
Upcoming readouts41 Phase 3
Market cap$2.2B
Cash & investments$430M~16 quarters at last loss rate
Recent 8-K filings1latest 2026-11-10

Upcoming readouts

Phase 1/2 HMB-002 (Part A)
Von Willebrand Disease (VWD); Von Willebrand Disease (VWD), Type 1 · NCT06754852
July 2027
Recruiting
Phase 1/2 HMB-001
Glanzmann Thrombasthenia · NCT06211634
August 2027
Ongoing
Phase 2 Sutacimig
Congenital Factor VII Deficiency · NCT07347249
November 2027
Recruiting
Phase 3 Sutacimig
Thrombasthenia · NCT07935356
November 2029
Recruiting

Cash position

Hemab Therapeutics Holdings Inc. reported $430M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-10). Its net loss for that quarter was $27M; at that rate the cash would last about 16 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-10

Companies working on similar indications

Discussion

No messages yet. If you follow COAG, you can start the conversation.
Track COAG in real time
See live implied volatility for COAG and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on COAG
Contact — questions or corrections about COAG: dukeupt@gmail.com